In vivo, we found that BBSKE combined with oxaliplatin exhibited a synergistic inhibitory effect on gastric tumor growth, and effectively reduced the activity of TrxR1 in tumor tissues, which was consistent with the in vitro results. Here, TXNRD1 is linked to neoplasm.